Issue of Equity

RNS Number : 0337H

Avacta Group PLC

14 May 2014

 



Avacta Group plc

("Avacta" or the "Group")

Issue of Equity

Avacta Group plc (AIM: AVCT), the global provider of proprietary diagnostic tools, consumables and reagents for human and animal healthcare, today announces that 3,779,411 Ordinary Shares of 0.1p ("new Ordinary Shares") have been issued by the Company pursuant to the exercise of share options by former employees.

Application will be made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 19 May 2014.

The total number of Ordinary Shares in issue following the above issue will be 4,029,831,367 each with voting rights.  No Ordinary Shares are held in Treasury.

The above figure of 4,029,831,367 shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FSA's Disclosure and Transparency Rules.

- Ends -

Enquiries:

Avacta Group plc		Tel:  [phone]
Alastair Smith, Chief Executive Officer		www.avacta.com
Tim Sykes, Chief Financial Officer
Numis Securities Limited		Tel:  [phone]
Michael Meade / Freddie Barnfield - Nominated Adviser		www.numiscorp.com
James Black - Corporate Broking
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

About Avacta Group plc - www.avacta.com

Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. Avacta operates through three divisions:

Avacta Analytical www.avactaanalytical.com	High throughput analysis instrument, Optim, to help reduce the cost and risk of drug development.
Avacta Animal Health www.avactaanimalhealth.com	Veterinary diagnostics reference laboratory, diagnostic kits and newly launched in-clinic blood analyser, Sensipod.
Avacta Life Sciences www.avactalifesciences.com	Novel non-antibody affinity reagents called Affimers, with a wide range of Life Science applications in diagnostics, drug and biomarker discover and biotech research and development.

Avacta joined AIM in August 2006 and is based in Wetherby, England.

 

END

 

 

IOEUOUKRSRAVAAR